Badanie skuteczności i bezpieczeństwa vimseltinibu u pacjentów z guzem olbrzymiokomórkowym błony maziowej

Tenosynovial Giant Cell Tumor (TGCT) is a condition that affects the joints, causing pain and stiffness. This study is focused on evaluating a new treatment called vimseltinib, which is being tested for its effectiveness and safety in patients with TGCT. The study is designed to compare the effects of vimseltinib with a placebo, which is a substance with no active medication, to see how well the treatment works.

The study is divided into two parts. In the first part, participants will receive either vimseltinib or a placebo without knowing which one they are taking. This is known as a "double-blind" study. In the second part, all participants will receive vimseltinib, and this phase is "open-label," meaning both the participants and the researchers know the treatment being given. The main goal is to assess the anti-tumor activity of vimseltinib using specific criteria to measure changes in the tumor size.

Participants will be monitored for changes in their condition, including pain and joint stiffness, over a period of time. The study will also track any side effects or adverse events that may occur. The results will help determine if vimseltinib is a safe and effective treatment option for people with Tenosynovial Giant Cell Tumor.